Table 1.
Baseline patient characteristics
| Characteristic | Pazopanib without ASM (n = 49) | Pazopanib with ASM (n = 42) |
|---|---|---|
| Age – no. (%) | ||
| <65 years old | 36 (74) | 27 (64) |
| ≥65 years old | 13 (26) | 15 (36) |
| Sex – no. (%) | ||
| Male | 25 (51) | 18 (43) |
| Female | 24 (49) | 24 (57) |
| Race – no. (%) | ||
| White | 40 (82) | 38 (91) |
| African American | 8 (16) | 4 (9) |
| Asian | 0 | 0 |
| Latin American | 0 | 0 |
| Other | 1 (2) | 0 |
| ECOGa – no. (%) | ||
| 0 | 22 (45) | 12 (29) |
| 1 | 17 (35) | 17 (41) |
| 2 | 7 (14) | 8 (19) |
| 3 | 1 (2) | 4 (10) |
| 4 | 0 | 0 |
| Sarcoma subtypeb – no. (%) | ||
| Leiomyosarcoma | 19 (39) | 11 (26) |
| Synovial | 4 (8) | 5 (12) |
| UPS | 6 (12) | 11 (26) |
| Liposarcoma | 3 (6) | 6 (14) |
| Other | 17 (35) | 9 (22) |
| Stage – no. (%) | ||
| I | 0 | 0 |
| II | 2 (4) | 1 (2) |
| III | 4 (8) | 1 (2) |
| IV | 43 (88) | 40 (96) |
| Prior chemotherapy – no. (%) | ||
| Yes | 37 (76) | 34 (81) |
| No | 12 (24) | 8 (19) |
ASM, acid suppressive medication; ECOG, Eastern Oncology Cooperative Group; UPS, undifferentiated pleomorphic sarcoma.aTwo patients in the pazopanib without ASM group and one patient in the pazopanib with ASM group did not have ECOG documented at baseline. bOther histological subtypes of sarcoma were spindle cell, epithelioid fibrosarcoma, myxofibrosarcoma, sarcomatoid, alveolar soft part sarcoma, angiosarcoma, large paraspindle cell, clear cell, and desmoplastic small round cell.